NeurAxis (NASDAQ:NRXS) vs. Cytosorbents (NASDAQ:CTSO) Head-To-Head Survey

Cytosorbents (NASDAQ:CTSO – Get Free Report) and NeurAxis (NASDAQ:NRXS – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

Insider and Institutional Ownership

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 7.8% of Cytosorbents shares are owned by insiders. Comparatively, 21.1% of NeurAxis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cytosorbents and NeurAxis’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytosorbents -45.06% -689.23% -41.26%
NeurAxis -492.76% N/A -641.25%

Valuation and Earnings

This table compares Cytosorbents and NeurAxis”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytosorbents $37.06 million 0.41 -$8.20 million ($5.80) -0.82
NeurAxis $6.53 million 8.34 -$14.63 million ($1.06) -4.83

Cytosorbents has higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cytosorbents has a beta of 1.49, suggesting that its share price is 49% more volatile than the S&P 500. Comparatively, NeurAxis has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for Cytosorbents and NeurAxis, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytosorbents 1 0 2 0 2.33
NeurAxis 0 1 1 0 2.50

Cytosorbents currently has a consensus target price of $104.75, suggesting a potential upside of 2,093.72%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 154.10%. Given Cytosorbents’ higher possible upside, research analysts plainly believe Cytosorbents is more favorable than NeurAxis.

Summary

Cytosorbents beats NeurAxis on 9 of the 14 factors compared between the two stocks.

About Cytosorbents

(Get Free Report)

Cytosorbents Corp. develops blood-purification technologies for use in hospitals and other clinical settings. Its products are designed to work with extracorporeal circuits, where blood is circulated outside the body and passed through a purification device. The company’s best-known product, CytoSorb, is an adsorber intended to remove certain inflammatory substances and other compounds from blood. It is used in areas such as critical care and cardiac surgery. Cytosorbents also develops DrugSorb-ATR, a device designed to remove certain blood-thinning drugs during cardiac procedures.

About NeurAxis

(Get Free Report)

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and functional pain conditions. Its approach uses percutaneous electrical nerve field stimulation (PENFS), which delivers mild electrical impulses through nerves associated with the brain-gut pathway. The company’s lead product, IB-Stim, is a wearable, minimally invasive device cleared by the U.S. Food and Drug Administration for use as an adjunctive treatment for functional abdominal pain associated with irritable bowel syndrome in patients ages 11 to 18 who have not responded to conventional therapy.

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.